Most chronic kidney diseases have a progressive evolution characterized by the gradual loss of glomerular filtration rate (GFR), electrolytic imbalance, reduced erythropoietin synthesis and activation of vitamin D. On many occasions, the progressive deterioration of renal function occurs, even when the etiologic factors responsible for the kidney disease are treated and/or eliminated as a result of an auto-sustained mechanism of inflammation and fibrosis. Moreover, chronic nephropathies are often associated with high blood pressure and increased urine protein excretion, being both risk factors of progression toward kidney failure. Many clinical studies have shown the efficacy of antihypertensive therapies, particularly the blockade of renin-angiotensin system, to lower the abnormal urinary protein excretion. Moreover, control of blood pressure and proteinuria slow the rate of renal function decline and in some cases even lead to recovery of kidney function avoiding the need for renal replacement therapies. The set of measures to achieve these results encompasses the term of "renoprotective therapy". However these achievements have been obtained in the setting of clinical trials, and need confirmation in the daily clinical practice. To this purpose a standardized multidrug intervention model that aims at normalizing the excretion of urinary proteins and stabilizing the renal function has been developed for the outpatient-clinic and named "Remission Clinic". The applicability of this protocol is aimed for all nephrology and diabetology centers. Through the use of a dedicated database computer network, it will be possible to share clinical, laboratory and treatment data, recorded for each patient enrolled in the Remission Clinic program. With this system, it will be possible to verify if the multidrug approach of the Remission Clinic will allow to improve the clinical course of chronic proteinuric nephropathy. All participants (centers) may access to the Remission Clinic website developed, updated and maintained by the Department of Bioengineering of the Mario Negri Institute, Bergamo, Italy.
Study Type
OBSERVATIONAL
Enrollment
1,500
Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò
Ranica, Bergamo, Italy
Ospedale Morgagni - Pierantoni - U.O. Nefrologia e Dialisi
Forlì, Forli', Italy
Asl 6 Sanluri-P.O. Nostra Signora di Bonaria - U.O. Nefrologia e Dialisi
San Gavino Monreale, Medio Campidano - VS, Italy
Ospedale C.G. Mazzoni Zona 13 ASUR Marche - U.O. Nefrologia e Dialisi
Ascoli Piceno, Italy
AORN Moscati - Avellino - U.O. Nefrologia e Dialisi
Avellino, Italy
A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi
Bergamo, Italy
A.O. Papa Giovanni XXIII Bergamo - U.O. Diabetologia
Bergamo, Italy
Azienda Ospedaliera G. Brotzu - U.O. Nefrologia e Dialisi
Cagliari, Italy
Ospedale Campo di Marte - USL 2 - U.O. Nefrologia
Lucca, Italy
ARNAS Ospedale Civico Di Cristina Benfratelli - U.O. Nefrologia e Dialisi
Palermo, Italy
...and 3 more locations
Glomerular Filtration Rate (GFR) estimated
Time frame: Changes from baseline at at least every 3 to 6 months for the duration of the study, an expected average of 10 years.
24 hour proteinuria
Time frame: Changes from baseline at at least every 3 to 6 months for the duration of the study, an expected average of 10 years.
Number of participants with fatal and non-fatal cardiovascular events
Sudden death, myocardial infarction, unstable angina, stroke, transient ischemic attack, lower limb amputation, coronary, carotid or peripheral vessel revascularization.
Time frame: Participants will be followed for the duration of the study, an expected average of 10years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.